Literature DB >> 28219772

Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection.

Manuel Ramos-Casals1, Anna Linda Zignego2, Clodoveo Ferri3, Pilar Brito-Zerón4, Soledad Retamozo5, Milvia Casato6, Peter Lamprecht7, Alessandra Mangia8, David Saadoun9, Athanasios G Tzioufas10, Zobair M Younossi11, Patrice Cacoub9.   

Abstract

Entities:  

Keywords:  DAAs; Extrahepatic manifestations; Hepatitis C virus; Rituximab

Mesh：

Substances：

Year:  2017        PMID： 28219772     DOI： 10.1016/j.jhep.2017.02.010

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  19 in total

1.  The combined polymorphisms of interleukin-6-174GG genotype and interleukin-10 ATA haplotype are associated with a poor quality of life in patients with chronic hepatitis C.

Authors:  Diego Alves Vieira; Luciana Rodrigues da Cunha; Cliviany Borges da Silva; Maria Thereza Bastos Almeida; Adriana Dias Gomes; César Lúcio Lopes de Faria; Rosângela Teixeira; Fernando Silva Neves; Gifone Aguiar Rocha; Fabrício Freire de Melo; Dulciene Maria de Magalhães Queiroz; Luciana Diniz Silva
Journal:  Qual Life Res       Date:  2019-02-07       Impact factor: 4.147

Review 2.  Impact of Direct Acting Antiviral Agent Therapy upon Extrahepatic Manifestations of Hepatitis C Virus Infection.

Authors:  Arpan Mohanty; Sarah Salameh; Adeel A Butt
Journal:  Curr HIV/AIDS Rep       Date:  2019-10       Impact factor: 5.071

Review 3.  Possible roles of exosomal miRNAs in the pathogenesis of oral lichen planus.

Authors:  Congcong Li; Hong He; Jiaqin Wang; Xinyu Xia; Mengyun Zhang; Qingzhu Wu
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

Review 4.  Advances in HCV and Cryoglobulinemic Vasculitis in the Era of DAAs: Are We at the End of the Road?

Authors:  Chalermrat Bunchorntavakul; Robert Mitrani; K Rajender Reddy
Journal:  J Clin Exp Hepatol       Date:  2017-12-07

5.  Improvement of Central Nervous System Vasculitis in a Patient with Chronic Hepatitis C Virus Infection after Treatment with an Interferon-Free Regimen.

Authors:  Sérgio Lima; Raquel Faria; Filipe Nery
Journal:  GE Port J Gastroenterol       Date:  2018-09-10

Review 6.  Timing Strategies of Direct-Acting Antivirals and Biologics Administration in HCV-Infected Subjects with Inflammatory Bowel Diseases.

Authors:  Nicola Imperatore; Fabiana Castiglione; Antonio Rispo; Anna Sessa; Nicola Caporaso; Filomena Morisco
Journal:  Front Pharmacol       Date:  2017-11-21       Impact factor: 5.810

Review 7.  Natural History of Hepatic and Extrahepatic Hepatitis C Virus Diseases and Impact of Interferon-Free HCV Therapy.

Authors:  Francesco Negro
Journal:  Cold Spring Harb Perspect Med       Date:  2020-04-01       Impact factor: 6.915

8.  Orbital Pseudotumor as an Extrahepatic Complication of Chronic HCV Infection.

Authors:  Owen Huang; Tina Shah; Divya Sundarapandiyan; Matthew J Akiyama
Journal:  Case Rep Infect Dis       Date:  2018-05-30

9.  Autoimmune Hepatitis During Ledipasvir/Sofosbuvir Treatment of Hepatitis C: A Case Report.

Authors:  Giovanni Covini; Elena Bredi; Salvatore Badalamenti; Massimo Roncalli; Alessio Aghemo; Massimo Colombo
Journal:  Hepatol Commun       Date:  2018-09-25

10.  Viral Hepatitis Strategic Information to Achieve Elimination by 2030: Key Elements for HIV Program Managers.

Authors:  Yvan Hutin; Daniel Low-Beer; Isabel Bergeri; Sarah Hess; Jesus Maria Garcia-Calleja; Chika Hayashi; Antons Mozalevskis; Annemarie Rinder Stengaard; Keith Sabin; Hande Harmanci; Marc Bulterys
Journal:  JMIR Public Health Surveill       Date:  2017-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.